Device Trial Radar · NCT07516444
VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Jul 28, 2026
Primary completion
Jun 2029
Study completion Jun 2036
Sponsor
- Lead sponsor
- VDyne, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation.
Conditions
- Tricuspid Valve Regurgitation
- Tricuspid Valve Disease
- Cardiovascular Diseases (CVD)
- Heart Valve Diseases
- Tricuspid Valve Insufficiency
- Severe Heart Valve Disease
- Randomized Controlled Trial (RCT)
- Symptomatic Tricuspid Regurgitation
Interventions
Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova SystemDevice
Subjects will undergo TTVR procedure with VDyne TriNova device and will continue to be managed on Optimal Medical Therapy (OMT).
Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE SystemDevice
Subjects will undergo TTVR procedure with Edwards EVOQUE device and will continue to be managed on Optimal Medical Therapy (OMT).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of major adverse events (MAEs)Time frame: 30 days post-procedure
- Composite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reinterventionTime frame: 12 months post-procedure
- Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)Time frame: 12 months post-procedure
1 more outcomes with a free account
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Banner Health
Phoenix, Arizona · Recruiting
Honor Health
Scottsdale, Arizona · Recruiting
Sutter Health/ California Pacific Medical Center
San Francisco, California · Recruiting
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.